Skip to main navigation news careers Overview Press Releases Events & Presentations Stock Information Analyst Coverage SEC Filings Corporate Governance Contact : Day High Day Low Volume 8:16 AM EST on Nov 09, 2021 Data Provided by Refinitiv. Minimum 15 minutes delayed. Investors Overview Aravive, Inc. is a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers. Aravive’s lead therapeutic, batiraxcept (formerly AVB-500), is a first-in-class ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth, tumor metastasis, resistance to treatment and decreased survival. Batiraxcept has the potential to be combined with multiple anticancer therapies across several tumor types, due to its novel mechanism of action and favorable safety profile. Batiraxcept has been granted Fast Track designation by the U.S. Food and Drug Administration and orphan drug designation by the European Commission in platinum resistant recurrent ovarian cancer. The Company is currently evaluating batiraxcept in a registrational Phase 3 trial in platinum resistant ovarian cancer, a Phase 1b/2 trial in second line plus, clear cell renal cell carcinoma, and a Phase 1b/2 trial in first-line treatment of pancreatic adenocarcinoma. Latest Corporate Presentation Aravive Corporate Presentation White Papers Novel Approaches Designed to Enhance the Efficacy of Cancer Treatments by Suppressing Mechanisms of Tumor Metastasis and Chemoresistance Source Gail McIntyre, Ph.D. Press Releases Aravive to Participate in Fireside Chat at Piper Sandler 33rd Annual Virtual Healthcare Conference November 15, 2021 Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma November 12, 2021 Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to be Presented at 2021 Society for Immunotherapy of Cancer Annual Meeting November 9, 2021 VIEW ALL PRESS RELEASES Email Alerts Print Page Share © 2021 Aravive Terms of Use | Privacy Policy